News

Press Release
RepliCel Receives European Patent for its Innovative Dermal Injector Technology
RCI-02 injector device promises the potential for unparalleled injection precision, the use of less anesthetic...
Press Release
RepliCel Life Sciences Inc. Announces Closing of Second Tranche of Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...
Press Release
RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin
Phase 1 clinical trial investigating the use of a patient-specific cell-based dermal rejuvenation product (RCS-01)...
Press Release
RepliCel Life Sciences Announces Leadership Transition
Lee Buckler, former VP Business & Corporate Development, appointed CEO President & Director; David Hall...
Press Release
RepliCel Life Sciences Inc. Announces Closing of First Tranche of Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...
As Seen In
How Japan ‘Changed the System’
Japan’s Bold Steps By: Iain Marlow ASUKE, JAPAN The Globe and Mail Last updated: Saturday, Nov....
Events
RepliCel Executives to Present at 9th World Congress for Hair Research in Miami
Conference brings together hair biologists, dermatologists, cosmetic scientists and leading biotech companies to discuss the...
Events
RepliCel Selected as One of This Year’s Top 20 Public Canadian Technology Companies
Canadian Innovation Exchange (CIX) Public Investor Day November 18 at Toronto’s MaRS Discovery District to...
As Seen In
Canada’s emerging cell therapy biotech industry
Canadian companies driving global breakthroughs in regenerative medicine By Kathryn Boothby To read this article...
Press Release
First Participants Enrolled in RepliCel’s Phase 1 Clinical Trial of its RCS-01 Dermatology Injectable
Testing the use of a cell-based injectable as a regenerative alternative for the global dermal...
Press Release
RepliCel Life Sciences Inc. Announces Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FORDISSEMINATION IN THE UNITED STATES...
Press Release
Industry Leader Geoff MacKay Joins RepliCel Life Sciences’ Board of Directors
VANCOUVER, BC – October 15, 2015 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP),...
Events
RepliCel Announces October Presentation and Partnering Meeting Schedule
VANCOUVER, BC – October 8, 2015 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP),...
Events
RepliCel Presenting at Two Upcoming Investment and Partnering Forums
A Chinese-based investor forum in Toronto and an aesthetics & dermatology conference in Newport Beach...
As Seen In
Japan’s regulatory gamble and what it means for the Industry
Navigating the Global Regulatory Landscape Written by: Lee Buckler & Colin Lee Novick The Follower...
Press Release
RepliCel Life Sciences Announces Initiation of Clinical Site and Participant Recruitment for European Skin Aging Study
Clinical trial site located at IUF Leibniz-Institut für umweltmedizinische Forschung GmbH in GermanyVANCOUVER, BC –...
As Seen In
Alan Leong of BioWatch Looks Beyond the Buzz for Solid Early-Stage Plays RP, CAPR, CTRV, CPXX, SRNE, SNSS
To read the full article as it appears on The Life Sciences Report, click here....
Press Release
RepliCel Life Sciences Cleared to Initiate Clinical Trial of RCS-01 for Dermal Rejuvenation
Patient recruitment will take place at the IUF Leibniz-Institut für umweltmedizinische Forschung GmbH in Germany...
Press Release
RepliCel Reports Second Quarter 2015 Financial Results
VANCOUVER, BC – August 28, 2015 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP),...
As Seen In
Harness Biotech Volatility with an Options Strategy: Theta Strategy Capital’s Eden Rahim
To read the full article as it appears on The Life Science Report, please click...

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.